Laboratory evidence to support the use of long-term adjuvant tamoxifen therapy for breast cancer.
Animal models all demonstrate that tamoxifen is tumouristatic in the case of breast tumours and long-term or indefinite therapy is required to prevent the appearance of tumours. When treatment is stopped, tumours appear spontaneously or can be encouraged to re-appear with oestrogen therapy. These data support the view that adjuvant clinical trials with tamoxifen should employ a 5- or 10-year treatment regimen.